Table 1.
Characteristics of men who have sex with men (MSM) and transgender women from the HVTN 505 vaccine trial study population.
| Characteristic | Controls (n = 103) | Cases (n = 103) | P value |
|---|---|---|---|
| Age (years), median (IQR) | 32 (25,40) | 27 (23, 33) | 0.004 |
| Age group (years) | 0.090 | ||
| 20-24 | 25 (24.3%) | 35 (34.0%) | |
| 25-29 | 18 (17.5%) | 28 (27.2%) | |
| 30-34 | 20 (19.4%) | 18 (17.5%) | |
| 35-39 | 14 (13.6%) | 6 (5.8%) | |
| 40-44 | 14 (13.6%) | 8 (7.8%) | |
| ≥45 | 12 (11.7%) | 8 (7.8%) | |
| Gender Identity, % | 0.748 | ||
| Male | 102 (99.0%) | 100 (97.1%) | |
| Female | 1 (1.0%) | 1 (1.0%) | |
| Transgender Female | 0 (0.0%) | 2 (1.9%) | |
| Race/ethnicity, % | 0.415 | ||
| Non-Hispanic White | 70 (70.0%) | 64 (62.1%) | |
| Non-Hispanic Black | 18 (17.5%) | 27 (26.2%) | |
| Hispanic | 8 (7.8%) | 8 (7.8%) | |
| Non-Hispanic other race/multiracial | 7 (6.8%) | 4 (3.9%) | |
| Behavioral risk score [14] | <0.001 | ||
| Low risk (score = 0) | 35 (34.0%) | 19 (18.4%) | |
| Low-medium risk (score = 0.46) | 29 (28.2%) | 18 (17.5%) | |
| Medium-high risk (score = 0.54) | 20 (19.4%) | 19 (18.4%) | |
| High risk (score = 1) | 19 (18.4%) | 47 (45.6%) | |
| Intention-to-treat trial arm | 0.016 | ||
| Placebo | 33 (32.0%) | 51 (49.5%) | |
| Vaccine | 70 (68.0%) | 52 (50.5%) | |
| Per-protocol trial arm | <0.001 | ||
| Placebo | 11 (10.7%) | 34 (33.0%) | |
| Vaccine | 92 (89.3%) | 69 (67.0%) | |
| Time before HIV infection (days), median (range) | 142 (17-361) | – | |
| Time before HIV infection, % | – | ||
| ≤3 months | – | 34 (33.0%) | |
| 3-9 months | – | 49 (47.6%) | |
| >9 months | – | 20 (19.4%) |
Note: Data are sample sizes and corresponding column percentages, unless otherwise indicated. P values were calculated from Fisher's exact tests, and do not account for the matched design of the study.